TGFB1 and COVID-19: In COVID-19 patients, the increased levels of TGF-β may occur to counteract the high inflammatory response (Russell et al., 2020), but it can also slow the recovery of disease in vivo by inhibiting the activity of the immune system in vivo (Sheng et al., 2015; Ferreira-Gomes et al., 2021).